The Comparative Effectiveness of Natalizumab and Anti-CD20 Monoclonal Antibodies in Relapsing-Remitting Multiple Sclerosis: A Real-World based Study

被引：0

作者：

Zeineddine, Maya ^{[1
,2
]}

Alroughani, Raed ^{[3
]}

Mohamed, Samar Farouk Ahmed ^{[4
]}

Al Mahdawi, Akram ^{[5
]}

Khoury, Samia ^{[6
]}

El Ayoubi, Nabil ^{[6
]}

Inshasi, Jihad ^{[7
,8
]}

Al Khaboori, Jaber ^{[9
]}

Al-Asmi, Abdullah ^{[10
,11
]}

Gouider, Riadh ^{[12
]}

Aljarallah, Salman ^{[13
]}

Al Khawajah, Nuha Marwan ^{[13
]}

Al Malik, Yaser ^{[14
,15
]}

Abulaban, Ahmad ^{[14
,15
]}

Makkawi, Seraj ^{[14
,15
,16
]}

Khojah, Osama ^{[14
,15
,16
]}

El Hajj, Taghrid ^{[17
]}

Massouh, Joelle ^{[18
]}

Alsalamat, Husam ^{[19
]}

Dimassi, Hani ^{[2
]}

al-hajje, Amal ^{[20
,21
]}

Salameh, Pascale ^{[20
,21
,22
,23
]}

Boumediene, Farid ^{[1
]}

Yamout, Bassem I. ^{[18
]}

机构：

[1] Univ Limoges, CHU Limoges, Inserm,Inst Epidemiol & Trop Neurol,Omega Hlth, U1094,IRD U270,EpiMaCT Epidemiol Chron Dis Trop Z, Limoges, France

[2] Lebanese Amer Univ, Sch Pharm, Byblos, Lebanon

[3] Amiri Hosp, Kuwait, Kuwait

[4] Ibn Sina Hosp, Kuwait, Kuwait

[5] Baghdad Med City Teaching Hosp, Baghdad, Iraq

[6] Amer Univ Beirut, Nehme & Therese Tohme Multiple Sclerosis Ctr, Med Ctr, Beirut, Lebanon

[7] Rashid Hosp, MS Dept, Dubai, U Arab Emirates

[8] Dubai Hlth Author, Dubai Med Coll, Dubai, U Arab Emirates

[9] Royal Hosp, Dept Neurol, Muscat, Oman

[10] Sultan Qaboos Univ, Neurol Unit, Dept Med, Coll Med & Hlth Sci, Muscat, Oman

[11] Sultan Qaboos Univ, Sultan Qaboos Univ Hosp, Muscat, Oman

[12] Razi Univ Hosp Mannouba, Clin Invest Ctr Neurosci & Mental Health, Dept Neurol, LR18SP03, Tunsi, Tunisia

[13] Med City, Riyadh, Saudi Arabia

[14] King Saud Bin Abdulaziz Univ Hlth Sci, Coll Med, Jeddah, Saudi Arabia

[15] Minist Natl Guard Hlth Affairs, Dept Neurosci, Jeddah, Saudi Arabia

[16] King Abdullah Int Med Res Ctr, Jeddah, Saudi Arabia

[17] Lebanese Univ, Fac Med Sci, Beirut, Lebanon

[18] Harley St Med Ctr, Neurol Inst, Abu Dhabi, U Arab Emirates

[19] Al Balqa Appl Univ, Fac Med, Al Salt 19117, Jordan

[20] Lebanese Univ, Fac Pharm, Beirut, Lebanon

[21] Natl Inst Publ Hlth Clin Epidemiol & Toxicol INSP, Beirut, Lebanon

[22] Lebanese Amer Univ, Sch Med, Byblos, Lebanon

[23] Univ Nicosia, Sch Med, Dept Primary Care & Populat Hlth, CY-2417 Nicosia, Cyprus

来源：

MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

O096/1296

引用

页码：91 / 92

页数：2

共 50 条

[31] Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study
Zhang, Yao
Yin, Hexiang
Zhang, Dingding
Xu, Yan
Peng, Bin
Cui, Liying
JOURNAL OF NEUROLOGY, 2022, 269 (09) : 4808 - 4816
[32] Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study
Zhang, Y.
Yin, H.
Zhang, D.
Xu, Y.
Peng, B.
Cui, L.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 888 - 889
[33] CD11c+ B cells in relapsing-remitting multiple sclerosis and effects of anti-CD20 therapy
El Mahdaoui, Sahla
Hansen, Marie Mathilde
von Essen, Marina Rode
Hvalkof, Victoria Hyslop
Hansen, Rikke Holm
Mahler, Mie Reith
Jennum, Poul
Sellebjerg, Finn
Christensen, Jeppe Romme
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (04): : 926 - 937
[34] Correction to: REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal
S. Batista
C. C. Nunes
J. J. Cerqueira
Ana Martins Silva
J. Correia de Sá
J. Ferreira
M. T. Mendonça
J. Pinheiro
V. Salgado
A. S. Correia
J. Sequeira
A. Costa
L. Sousa
Neurological Sciences, 2021, 42 : 767 - 767
[35] REAL-LIFE EFFECTIVENESS OF NATALIZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): A REGISTRY ANALYSIS
Danko, D.
Manca, A.
Mor, Z.
Csepany, T.
VALUE IN HEALTH, 2014, 17 (03) : A56 - A57
[36] Comparative Effectiveness and Risk of Severe Infection in Adult Patients with Multiple Sclerosis Treated with Diroximel Fumarate versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis
Obeidat, Ahmed Z.
Betz, Michelle
Farber, Rebecca
Goff, Erica
Gudesblatt, Mark
Le Hua
Mao-Draayer, Yang
Robertson, Derrick
Santoro, Jonathan
Wang, Tony
Gomes, Daniel
Bozin, Ivan
Mendoza, Jason
Bian, Boyang
Lewin, Jim
Belviso, Nicholas
Shankar, Sai
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1242 - 1243
[37] Characteristics of real-world disability improvement in relapsing-remitting multiple sclerosis patients treated with natalizumab in the TYSABRI® Observational Program
Wiendl, H.
Butzkueven, H.
Kappos, L.
Spelman, T.
Trojano, M.
Dong, Q.
Campbell, N.
Ho, P. -R.
Licata, S.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 373 - 373
[38] Real world comparative effectiveness data of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: results from a systematic literature review
Lang, S.
Wolff, R.
Annovazzi, P.
Baroncini, D.
Kalincik, T.
Koch-Henriksen, N.
Laplaud, D-A.
Acosta, C.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 610 - 611
[39] COST-EFFECTIVENESS OF NATALIZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN RUSSIA
Matveev, N., V
Sabanov, A., V
Luneva, A., V
VALUE IN HEALTH, 2014, 17 (03) : A60 - A60
[40] Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study
Costa-Frossard Franca, Lucienne
Lallana, Virginia Meca
Labiano-Fontcuberta, Andres
Blasco, Rosario
Monreal, Enric
Gines, Maria Luisa Martinez
Aguirre, Clara
Munoz, Julia Sabin
de la Maza, Susana Sainz
Cuello, Juan Pablo
Diaz-Perez, Carolina
Garcia, Juan Luis Chico
Ros, Alberto Lozano
Jorge, Fernando Rodriguez
Martinez, SusanaMartinez
Dominguez, Jose Manuel Garcia
CNS DRUGS, 2024, 38 (04) : 291 - 302

← 1 2 3 4 5 →